Last reviewed · How we verify
PIXANTRONE
At a glance
| Generic name | PIXANTRONE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2012 |
Approved indications
Common side effects
Key clinical trials
- Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (PHASE2)
- Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients
- A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (PHASE2)
- Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment (PHASE1)
- Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) (PHASE1, PHASE2)
- Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study (PHASE1, PHASE2)
- GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma (PHASE2)
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PIXANTRONE CI brief — competitive landscape report
- PIXANTRONE updates RSS · CI watch RSS